MoonLake Immunotherapeutics (MLTX) Total Non-Current Liabilities (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Total Non-Current Liabilities of $100.2 million for Q1 2026, up 34.18% year-over-year from $74.7 million in Q1 2025, and up 34.59% quarter-over-quarter from $74.5 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $100.2 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 34.18% year-over-year to $100.2 million; the TTM figure through Mar 2026 stood at $100.2 million (up 34.18% YoY), while the FY2025 annual figure was $74.5 million, up 3482.2% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $100.2 million, up from $74.5 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $100.2 million in Q1 2026, with the low at $4985.0 in Q3 2022.
- The 5-year median for Total Non-Current Liabilities is $2.6 million (2024), against an average of $25.9 million.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities soared 5285.82% in 2023, then tumbled 32.57% in 2024.
- MoonLake Immunotherapeutics' Total Non-Current Liabilities stood at $411157.0 in 2022, then jumped by 649.94% to $3.1 million in 2023, then slumped by 32.57% to $2.1 million in 2024, then soared by 3482.2% to $74.5 million in 2025, then jumped by 34.59% to $100.2 million in 2026.
- Business Quant data shows MLTX's Total Non-Current Liabilities at $100.2 million in Q1 2026, $74.5 million in Q4 2025, and $74.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 100.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100.36 Mn |
| Mar 31, 2026 | 100.24 Mn |
| Dec 31, 2025 | 74.47 Mn |
| Sep 30, 2025 | 74.78 Mn |
| Jun 30, 2025 | 74.79 Mn |
| Mar 31, 2025 | 74.70 Mn |
| Dec 31, 2024 | 2.08 Mn |
| Sep 30, 2024 | 2.63 Mn |
| Jun 30, 2024 | 2.56 Mn |
| Mar 31, 2024 | 2.82 Mn |
| Dec 31, 2023 | 3.08 Mn |
| Sep 30, 2023 | 268,483.00 |
| Jun 30, 2023 | 376,614.00 |
| Mar 31, 2023 | 405,255.00 |
| Dec 31, 2022 | 411,157.00 |
| Sep 30, 2022 | 4,985.00 |
| Jun 30, 2022 | 18,588.00 |
| Dec 31, 2021 | 239,860.00 |